Abstract: Described herein are methods for reducing ventricular tachycardia/ventricular fibrillation (VT/VF), methods for reducing implantable cardioverter-defibrillator device (ICD) shocks, methods for reducing CV hospitalization, ER visits, CV death or SCD in patients having implantable cardiac devices or CRT, and methods for reducing the use of ICD in a human patient without prior VT/VF, by administering an effective amount of the potent and selective late sodium ion channel blocker Compound 1.

Abstract: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.